TheraRadar
Data updated: Jun 28, 2026

ERRIN (norethindrone) · Dr. Reddy's

Women's Health Approved 2002-10-21

Errin (norethindrone) is a progestin-only oral contraceptive (POP) indicated for the prevention of pregnancy. It provides a daily hormonal contraceptive option, particularly for patients who prefer or require an estrogen-free regimen.

Source: FDA Label • Progestin

How ERRIN Works

This medication works by thickening the cervical mucus to block sperm penetration and suppressing ovulation in many users. It also lowers midcycle hormone peaks, slows the movement of the egg through the fallopian tubes, and alters the uterine lining to prevent conception.

Source: FDA Label
NDA
Small Molecule
1
Indication
--
Phase 3 Trials
23
Years on Market

Details

Status
Prescription
First Approved
2002-10-21
Routes
ORAL-28
Dosage Forms
TABLET

Companies

Active Ingredient: NORETHINDRONE

ERRIN Approval History

2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
4 FDA actions from 2002 to 2025
Oct 2025 SUPPL
Label · Labeling
Apr 2015 SUPPL
Label · Labeling
Jun 2011 SUPPL
Label · Labeling

What ERRIN Treats

1 indications

ERRIN is approved for 1 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

ERRIN Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ERRIN

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMABELZ
ESTRADIOL
1 shared
Lupin
Shared indications:
ANNOVERA
ETHINYL ESTRADIOL
1 shared
MAYNE PHARMA INC
Shared indications:
ASHLYNA
ETHINYL ESTRADIOL
1 shared
GLENMARK PHARMS LTD
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT03106454 HS-09-00669 Ph 3 completed Ovulation Incidence in Oral Contraceptive Users
NCT02652650 CR108093 63623872FLZ1009, 2015-000639-34 Ph 1 completed A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ERRIN FDA Label Details

Indications & Usage

1. Indications Progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. Efficacy If used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. However, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. Table 1 lists the pregnancy rates for users of all major methods of contraception. Table 1: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year...

Track ERRIN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.